Selective internal radiation therapy (SIRT) in metastatic colorectal cancer (mCRC): safety, efficacy and survival outcomes from the South Australian Registry (#99)

8:30 AM

Adeola Ayoola

Formation kinetics of M(III)DOTA complexes in aqueous solution and water–ethanol mixtures. (#100)

8:30 AM

Zsolt Baranyai

New tris(hydroxypyridinone) chelators for ⁶⁸Ga PET imaging (#101)

8:30 AM

Philip J Blower

Chelator-free Radiolabeling of Iron Oxide Nanoparticles with ⁶⁸Ga for Dual Modality PET/MR Imaging (#102)

8:30 AM

Penelope Bouziotis

US national reader training and education initiatives for Ga-68-labelled DOTATATE, DOTATOC, and PSMA (#104)

8:30 AM

John J Sunderland

Influence of Post therapy 131I SPECT/CT on risk stratification in Patients with Differentiated thyroid cancer (#105)

8:30 AM

SATYAWATI DESWAL

In-vitro dose calibration of the DNA damage assay for internal irradiation of blood lymphocytes with the PET nuclide ⁶⁸Ga (#106)

8:30 AM

Uta Eberlein

Physico-chemical characterization of Ga(III)-complexes formed with DATA chelators (#107)

8:30 AM

Edit Farkas

3D dosimetry using Monte-Carlo simulation (GATE) compared to biological toxicity observed in a first in man phase I trial of radioimmunotherapy targeting synovial sarcoma metastases (SS). (#108)

8:30 AM

Anne Laure ALG Giraudet

Evaluation of glomerular kidney function with ⁶⁸Ga-DTPA in small animal PET/CT (#109)

8:30 AM

Daniel Guendel

Development and evaluation of the new ligand NOTET for the complexation of ⁶⁸Ga (#110)

8:30 AM

Leena Hogan

Optimization of threshold method for volume and activity determinations by using SPECT Phantom for possible clinical use in predicting response to regeneration and targeted liver therapies. (#112)

8:30 AM

Amritjyot Kaur

Robust radiopharmaceutical production, proven quality and high activity – how to have it all (#113)

8:30 AM

Melissa J. Latter

Biodegradable star polymers: In vitro stability assessment of ⁶⁴Cu- and ⁶⁷Ga-NOTA stars (#114)

8:30 AM

Nigel A Lengkeek

A Novel CCK2/Gastrin Receptor-Localizing Peptide Probe for Personalized Diagnosis and Therapy of Medullary Thyroid Carcinoma - Gran-T-MTC enrolls patients in a multicentre Phase I Study (#116)

8:30 AM

Renata Mikolajczak

Rapid Synthesis of ⁶⁸Ga-MAA for routine application in lung perfusion imaging using PET/CT   (#117)

8:30 AM

Richard P Baum

The Quest to Achieving a Concerted Cancer Treatment: Challenges in Nanotheranostics Delivery  (#118)

8:30 AM

Yaw Opoku-Damoah

Cyclen-based semicarbazone chelators of bismuth-213 for α-radiotherapy (#119)

8:30 AM

Brett M Paterson

Diagnostic performance of 99mTc-MDM brain SPECT in Glioma:  A comparison with contrast enhanced MRI Imaging for diagnostic workup of primary/ residual/recurrent glioma  (#120)

8:30 AM

Nisha Rani

⁶⁸Ga-PSMA PET/CT Brain imaging – a feasibility study. (#121)

8:30 AM

Arun Sasikumar

To evaluate the role of Lutetium-177 (Lu-177) tin colloid radiosynovectomy (RSV) in patients with inflammatory knee joint conditions who are not responding to conventional modalities in a setup where Re-188 & Y-90 not available. (#122)

8:30 AM

Shamim Ahmed Shamim

Extraordinary Similarities of Formation and Dissociation Kinetics of Fe^III- and Ga^III- TRAP-Pr Complexes (#123)

8:30 AM

Imre Toth

Theranostic in patients with recurring  Glioblastoma Multiforme (GBM): ⁶⁴CuCl₂ (#124)

8:30 AM

Gianluca Valentini

Critical aspects of ⁶⁸Ga production and chemistry in relation to clinical applications (#127)

8:30 AM

Irina Velikyan

RGD imaging serve as a surrogate for molecular phenotyping and prognosis: A Prospective Study of ^99mTc-3PRGD2 SPECT/CT in 226 Patients with Suspected Lung Cancer (#128)

8:30 AM

Feng Wang

The Role of ^99mTc-galacto-RGD₂ SPECT/CT in the Clinical Management of Refractory Thyroid Cancer (#129)

8:30 AM

Feng Wang